Antibody-Free Glycogen Nanoparticles Engage Human Immune T Cells for Intracellular Delivery of Small Drugs or mRNA

T cells play a major role in immune defense against viral infections and diseases such as cancer. Accordingly, developing nanoparticle (NP) systems to effectively deliver therapeutics to T cells is of interest. However, NP-mediated delivery of drugs to T cells is challenging because of the nonphagocytic nature of T cells. To engage T cells and induce cellular internalization, NPs are typically decorated with specific receptor-targeting antibodies, often using laborious and costly procedures. Herein, we report that natural glycogen NPs (i.e., nanosugars) with different sizes (20-80 nm) and surface charges (neutral and positively charged) engage Jurkat T cells, undergo intracellular trafficking, and release encapsulated drug without the use of receptor-targeting antibodies. Specifically, glycogen-resveratrol constructs are employed to reactivate HIV-1 latently infected Jurkat T cells (J-Lat A2) and trigger proviral expression. Both neutral and positively charged glycogen NPs engage with J-Lat A2 cells. Large (84 ± 29 nm) and positively charged (23 ± 5 mV) NPs, denoted phytoglycogen-ethylenediamine (PG<sub>EDA</sub>) NPs, readily associate with the cell membrane and are internalized (60%) in J-Lat A2 cells but remain confined in the endocytic vesicles, with moderate reactivation of latent HIV-1 (4.7 ± 0.5%). Conversely, small (21 ± 5 nm) and positively charged (10 ± 6 mV) NPs, bovine glycogen-EDA (BG<sub>EDA</sub>) NPs, associate slowly with T cells but show nearly 100% internalization and efficient endosomal escape properties, resulting in 1.5-fold higher reactivation of latent HIV-1 in T cells. PG<sub>EDA</sub> NPs and BG<sub>EDA</sub> NPs are also internalized by primary human T cells (>90% cell association) and enable the transfection of mRNA, with BG<sub>EDA</sub> NPs showing a 2-fold higher transfection than PG<sub>EDA</sub> NPs. This work highlights the potential of BG<sub>EDA</sub> NPs for the effective intracellular delivery of small-molecule drugs and mRNA in T cells.

Authors

Institutions

Publication Details

Journal
ACS Nano
Published
2024-10-11
DOI
https://doi.org/10.1021/acsnano.4c09156
Citations
5
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
1.17

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Antibody-Free Glycogen Nanoparticles Engage Human Immune T Cells for Intracellular Delivery of Small Drugs or mRNA

Darryl N. Johnson, Frank S Caruso, Soraia Fernandes, Marco Cassani et al.
5 citations
ACS Nano
RNA Interference and Gene Delivery
1.17
article

Antibody-Free Glycogen Nanoparticles Engage Human Immune T Cells for Intracellular Delivery of Small Drugs or mRNA

Darryl N. Johnson, Frank S Caruso, Soraia Fernandes, Marco Cassani, Francesca Cavalieri, Giancarlo Forte, Miriam Quattrociocchi, Giulio Savazzi
article en
5 citations

Abstract

T cells play a major role in immune defense against viral infections and diseases such as cancer. Accordingly, developing nanoparticle (NP) systems to effectively deliver therapeutics to T cells is of interest. However, NP-mediated delivery of drugs to T cells is challenging because of the nonphagocytic nature of T cells. To engage T cells and induce cellular internalization, NPs are typically decorated with specific receptor-targeting antibodies, often using laborious and costly procedures. Herein, we report that natural glycogen NPs (i.e., nanosugars) with different sizes (20-80 nm) and surface charges (neutral and positively charged) engage Jurkat T cells, undergo intracellular trafficking, and release encapsulated drug without the use of receptor-targeting antibodies. Specifically, glycogen-resveratrol constructs are employed to reactivate HIV-1 latently infected Jurkat T cells (J-Lat A2) and trigger proviral expression. Both neutral and positively charged glycogen NPs engage with J-Lat A2 cells. Large (84 ± 29 nm) and positively charged (23 ± 5 mV) NPs, denoted phytoglycogen-ethylenediamine (PG<sub>EDA</sub>) NPs, readily associate with the cell membrane and are internalized (60%) in J-Lat A2 cells but remain confined in the endocytic vesicles, with moderate reactivation of latent HIV-1 (4.7 ± 0.5%). Conversely, small (21 ± 5 nm) and positively charged (10 ± 6 mV) NPs, bovine glycogen-EDA (BG<sub>EDA</sub>) NPs, associate slowly with T cells but show nearly 100% internalization and efficient endosomal escape properties, resulting in 1.5-fold higher reactivation of latent HIV-1 in T cells. PG<sub>EDA</sub> NPs and BG<sub>EDA</sub> NPs are also internalized by primary human T cells (>90% cell association) and enable the transfection of mRNA, with BG<sub>EDA</sub> NPs showing a 2-fold higher transfection than PG<sub>EDA</sub> NPs. This work highlights the potential of BG<sub>EDA</sub> NPs for the effective intracellular delivery of small-molecule drugs and mRNA in T cells.

ACS NanoVol. 18(42)
University of Rome Tor Vergata (IT), The University of Melbourne (AU), King's College London (GB), King's College School (GB), RMIT University (AU)
British Heart Foundation, RMIT University, Australian Research Council, National Health and Medical Research Council, H2020 Marie Skłodowska-Curie Actions
Zero hunger
Openalex Percentile: Top 21%
RNA Interference and Gene Delivery
1.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.